预测膀胱尿路上皮癌临床结局的影像基因组学特征
该研究纳入62例膀胱尿路上皮癌患者的RNA测序数据、影像组学特征和临床参数,构建基于影像组学特征和基因表达谱的预后特征及多组学列线图,结果显示影像组学和转录组学特征可显著分层无进展间期,列线图预测能力优良,功能富集分析提示影像组学特征可反映血管生成状态。
要点
- 基于增强CT影像组学特征和转录组学特征可对膀胱尿路上皮癌患者无进展间期进行风险分层。
- 整合影像组学、转录组学和临床特征的多组学列线图对无进展间期显示出优良的预测能力。
- 功能富集分析提示所构建的影像组学特征可反映膀胱尿路上皮癌患者的血管生成状态。
核心结论
- 整合增强CT影像组学、转录组学和临床特征的多组学列线图改善了膀胱尿路上皮癌患者无进展间期的预测,是肿瘤精准医学可行且实用的参考。
研究设计与样本
- 研究纳入62例膀胱尿路上皮癌患者的RNA测序数据、影像组学特征和临床参数,采用LASSO Cox分析构建基于影像组学特征和基因表达谱的预后特征,并整合影像组学、转录组学和临床病理数据开发多组学列线图。
诊断标准与关键数值
- 影像组学特征和转录组学特征在无进展间期方面将膀胱尿路上皮癌患者显著分层为高风险组和低风险组。
- 在校正临床参数后的多变量分析中,两个风险模型均为独立预后因素。
- 列线图对膀胱尿路上皮癌患者无进展间期显示出优良的预测能力。
临床应用与阅片要点
- 作者认为整合增强CT影像组学、转录组学和临床特征的列线图是肿瘤精准医学可行且实用的参考。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the integrative value of contrast-enhanced computed tomography (CECT), transcriptomics data and clinicopathological data for predicting the survival of bladder urothelial carcinoma (BLCA) patients.
METHODS: RNA sequencing data, radiomics features and clinical parameters of 62 BLCA patients were included in the study. Then, prognostic signatures based on radiomics features and gene expression profile were constructed by using least absolute shrinkage and selection operator (LASSO) Cox analysis. A multi-omics nomogram was developed by integrating radiomics, transcriptomics and clinicopathological data. More importantly, radiomics risk score-related genes were identified via weighted correlation network analysis and submitted to functional enrichment analysis.
RESULTS: The radiomics and transcriptomics signatures significantly stratified BLCA patients into high- and low-risk groups in terms of the progression-free interval (PFI). The two risk models remained independent prognostic factors in multivariate analyses after adjusting for clinical parameters. A nomogram was developed and showed an excellent predictive ability for the PFI in BLCA patients. Functional enrichment analysis suggested that the radiomics signature we developed could reflect the angiogenesis status of BLCA patients.
CONCLUSIONS: The integrative nomogram incorporated CECT radiomics, transcriptomics and clinical features improved the PFI prediction in BLCA patients and is a feasible and practical reference for oncological precision medicine.
KEY POINTS: • Our radiomics and transcriptomics models are proved robust for survival prediction in bladder urothelial carcinoma patients. • A multi-omics nomogram model which integrates radiomics, transcriptomics and clinical features for prediction of progression-free interval in bladder urothelial carcinoma is established. • Molecular functional enrichment analysis is used to reveal the potential molecular function of radiomics signature.
引用
- Lin P, Wen DY, Chen L, et al. A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma. Eur Radiol. 2019. PMID: 31396730. doi:10.1007/s00330-019-06371-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。